Mereo BioPharma Group plc (LON:0A9G)

Market Cap	349.22M
Revenue (ttm)	746.10K
Net Income (ttm)	-33.81M
Shares Out	n/a
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,551
Average Volume	2,947
Open	2.870
Previous Close	2.860
Day's Range	2.870 - 2.965
52-Week Range	1.796 - 4.001
Beta	0.85
RSI	44.87
Earnings Date	Mar 28, 2025

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 33
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9G

Financial Performance

Financial numbers in USD